Cancer ResearchDepartment of Thoracic Surgery

Our research is funded by the University of Freiburg as well as the German Consortium for Translational Cancer Research (DKTK) as well as through industry collaboration grants.

Additional third party funding is available for the following projects:

2026 - 2027
German Cancer Consortium (Deutsches Konsortium für Translationale Krebsforschung DKTK)
hitFGFR: Effective FGFR targeting by specific combinatorial approaches with targeted and immune checkpoint inhibition
(Jointly with Prof. Dr. Heiko Becker, Prof. Dr. Lena Illert)

2025 - 2028
German Research Foundation (DFG) - SFB 1453 NephGen
Understanding differential disease manifestations of VHL mutations via the plurality of their molecular functions
(Jointly with Dr. Athina Ganner)

2025 - 2026
German Research Foundation (DFG)
Epigenetic causes and synthetic vulnerabilities to overcome FGFRi resistance in FGFR3-aberrant bladder cancer
(From UcarE Research Group - FOR 5476)

2021 - 2025
German Cancer Consortium (Deutsches Konsortium für Translationale Krebsforschung DKTK)
MTB-TAILOR: Treatment Prediction and Reverse Translation of the Molecular Tumor Board Freiburg
(jointly with Prof. Dr. Anna-Lena Illert, Dr. Carla Tangermann, Prof. Dr. Tilman Brummer)

 

Past Funding:

2022 - 2025
German Research Foundation (DFG)
Mechanisms of nonstop mutations in tumor suppressor genes
(associated with the SFB 1453 NephGen)

2020 - 2023
German Cancer Aid (Deutsche Krebshilfe)
Efficacy, molecular determinants and mechanisms of a combination therapy of ATRA and DNA-hypomethylating agents in lung adenocarcinoma
(together with Prof. Dr. Michael Lübbert)

2020 - 2023
German Cancer Aid (Deutsche Krebshilfe)
RNA-dependent Functions in Mitosis and Cancer
(Heidelberg)

2021 - 2022
Wilhelm Sander Foundation
RNA Damage Signaling in Response to Therapy: Mechanisms and functions in the cellular response to cytotoxic stress and RNA degradation
(Heidelberg)

2018 - 2021
German Research Foundation (DFG)
Defining the mechanisms of a new class of cancer mutations in the tumor suppressor genes SMAD4, PTEN and CDKN2A